Defining patient risks from expanded preventive therapies.

@article{Tolman2000DefiningPR,
  title={Defining patient risks from expanded preventive therapies.},
  author={Keith G. Tolman},
  journal={The American journal of cardiology},
  year={2000},
  volume={85 12A},
  pages={15E-9E}
}
In clinical trials, all lipid-lowering agents have been associated with mild, asymptomatic elevations of alanine aminotransferase (ALT) and asparate aminotransferase enzymes. This, along with the fact that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are hepatotoxic in some animals, led the US Food and Drug Administration (FDA) to recommend monitoring of liver enzymes for all lipid-lowering agents, except the bile acid sequestrants. Because the drugs act by different… CONTINUE READING
22 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…